This Article Full Text Full Text (PDF) All Versions of this Article: 200407-863OCv1 172/2/250    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Griffith, D. E. Articles by Wallace, R. J. Search for Related Content PubMed PubMed Citation Articles by Griffith, D. E. Articles by Wallace, R. J., Jr.

Ethambutol Ocular Toxicity in Treatment Regimens for Mycobacterium avium Complex Lung Disease

Departments of Medicine and Microbiology, University of Texas Health Center, Tyler, Texas; and Louisiana State University Health Science Center, Shreveport, Louisiana

Correspondence and requests for reprints should be addressed to David E. Griffith, M.D., Professor of Medicine, University of Texas Health Center, 11937 U.S. Highway 271, Tyler, TX 75708. E-mail: david.griffith{at}uthct.edu

Ethambutol (EMB) is an important component of multidrug treatment regimens for Mycobacterium avium complex lung disease. Ocular toxicity is the most important potential EMB toxicity, especially in the elderly population with M. avium complex lung disease. Two hundred twenty-nine patients with M. avium complex lung disease, 55% women and 53% with nodular/bronchiectatic disease, received a mean of 16.1 ± 10.8 months of multidrug therapy that included EMB. Fifty patients (22%) were known to have preexisting ocular disease. While on EMB, 97 (42%) patients consulted an opthalmologist and 24 (10%) stopped EMB at least temporarily. Eight of 139 patients (6%) on daily therapy were diagnosed with EMB ocular toxicity, whereas 0 of 90 patients on intermittent therapy had EMB ocular toxicity (p = 0.05). All patients with EMB ocular toxicity developed symptoms between outpatient clinic appointments; none were diagnosed with routine visual acuity and color vision testing. All patients with EMB ocular disease returned to baseline ocular status after discontinuation of EMB. Intermittent EBM administration was associated with less ocular toxicity than daily EMB administration in this patient population.

Key Words: ethambutol • Mycobacterium avium complex

This article has been cited by other articles:

				K. C. Chang, C. C. Leung, and C. M. Tam Toward Optimizing Treatment for Mycobacterium avium Complex Lung Disease Am. J. Respir. Crit. Care Med., April 15, 2007; 175(8): 860 - 860. [Full Text] [PDF]

				D. E. Griffith, T. Aksamit, B. A. Brown-Elliott, A. Catanzaro, C. Daley, F. Gordin, S. M. Holland, R. Horsburgh, G. Huitt, M. F. Iademarco, et al. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases Am. J. Respir. Crit. Care Med., February 15, 2007; 175(4): 367 - 416. [Full Text] [PDF]

				D. E. Griffith, B. A. Brown-Elliott, B. Langsjoen, Y. Zhang, X. Pan, W. Girard, K. Nelson, J. Caccitolo, J. Alvarez, S. Shepherd, et al. Clinical and Molecular Analysis of Macrolide Resistance in Mycobacterium avium Complex Lung Disease Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 928 - 934. [Abstract] [Full Text] [PDF]

				P. K. Lam, D. E. Griffith, T. R. Aksamit, S. J. Ruoss, S. M. Garay, C. L. Daley, and A. Catanzaro Factors Related to Response to Intermittent Treatment of Mycobacterium avium Complex Lung Disease Am. J. Respir. Crit. Care Med., June 1, 2006; 173(11): 1283 - 1289. [Abstract] [Full Text] [PDF]

				W. W. Yew and C. C. Leung Update in tuberculosis 2005. Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 491 - 498. [Full Text] [PDF]

				Ethambutol Ocular Toxicity: Intermittent Dosing Might Be Safer Journal Watch Infectious Diseases, August 5, 2005; 2005(805): 8 - 8. [Full Text]